HPV-16/18 vaccine / Walvax - LARVOL DELTA

Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women (clinicaltrials.gov) - P=N/A | N=5372 | Active, not recruiting | Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

New trial • Cervical Cancer • Gynecologic Cancers • Gynecology • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor • Vaginal Cancer • Vulvar Cancer

Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial. (PubMed, Vaccine) - "Immune responses to two doses of HPV-2 vaccine in adolescent girls were non-inferior to those after three doses in young women, an age cohort in which clinical efficacy of HPV-2 against cervical cancer has been demonstrated."

Clinical • Head-to-Head • Journal • Cervical Cancer • Oncology • Solid Tumor

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females. (PubMed, Hum Vaccin Immunother) - "Adverse events occurred at similar rates after vaccine and placebo (69.8% vs. 72.5%, p = .308), including solicited local reactions and systemic adverse events which were mainly mild-to-moderate. The bivalent HPV16/18 vaccine was well tolerated and induced high levels of neutralizing antibodies in all age groups which persisted at high levels to 48 months in the 9-17-year-old age group which would be the target for HPV vaccination campaigns."

Clinical • Journal • Oncology

Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial. (PubMed, Vaccine) - "The pichia pastoris-expressed bivalent HPV vaccine was safe and immunogenic in Chinese females aged 9-45 years. The low dosage (0.5 mL) was selected for further immunogenicity and efficacy study."

Clinical • Journal • P1 data • Oncology

Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females (clinicaltrials.gov) - P2 | N=900 | Completed | Sponsor: Shanghai Zerun Biotechnology Co.,Ltd | Unknown status ➔ Completed

Trial completion • Gynecology • Infectious Disease • Oncology

A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. (clinicaltrials.gov) - P3 | N=12000 | Completed | Sponsor: Shanghai Zerun Biotechnology Co.,Ltd | Unknown status ➔ Completed

Trial completion • Gynecology • Infectious Disease • Oncology